Screen 100-1000x more VHH antibody sequences with the largest libraries on the market
Combining the largest and most diverse synthetic VHH libraries available with our proprietary, cell-free CIS display technology means that these uniquely vast libraries can reach their full potential in under half the time of traditional immunisation methods.
Appetite for destruction: ‘Plug and play’ targeted protein degradation using synthetic VHH antibodies to take out tricky targets
Novel VHH protein degraders developed using Isogenica’s VHH antibody libraries show anti-tumour activity in vivo.
Passionate about patient outcomes
With a shared passion for discovery and a collaborative spirit, our team works to advance the field and support the development of ground-breaking therapies. Get to know the faces behind our pioneering work and see why we are trusted partners in the journey from concept to cure.
Connect with us
Join us at BIO-Europe Milan – March 17-19, 2025
Connect with Isogenica at BIO-Europe Spring in Milan from March 17–19, 2025. Our team is eager to showcase how our VHH antibody technology is...
Stay up to date
Isogenica and Cube Biotech Unite to Accelerate GPCR Therapeutics
Isogenica, a global leader in synthetic VHH antibody discovery, has announced a strategic collaboration with Cube Biotech, experts in stabilised protein technologies, to tackle one of the most complex challenges in drug discovery: G protein-coupled receptors (GPCRs).
Isogenica Ltd. and Axxam S.p.A. Announce Collaboration to Provide Unique VHH Antibody Discovery Solutions
Isogenica is pleased to welcome both Paul Clewlow and Trevor Phillips as our new Non-Executive Directors to the team.
Isogenica is proud to announce two new Non-Executive Directors
Isogenica is pleased to welcome both Paul Clewlow and Trevor Phillips as our new Non-Executive Directors to the team.